U.S. FDA Approves Clinical Trials for Repositioning of Dong-A ST’s Diabetes Drug 'Suganon' as a CAVD treatment
U.S. FDA Approves Clinical Trials for Repositioning of Dong-A ST’s Diabetes Drug 'Suganon' as a CAVD treatment - Businesskorea
http://www.businesskorea.co.kr/news/articleView.html?idxno=52231
REDNVIA Co., Ltd.
11F, 88, Olympic-ro 43-gil, Songpa-gu, Seoul,
[05505] Republic of Korea
Tel:+82-2-2039-1217 Fax: +82-70-8280-1218
For Investor relations: rednvia_contact@rednvia.com
Copyright © REDNVIA Co., Ltd. All right reserved.
